健择联合顺铂每周用药治疗晚期非小细胞肺癌的临床观察

目的：评价健择联合顺铂每周用药治疗晚期非小细胞肺癌的疗效和毒性反应。方法：37例晚期非小细胞肺癌患者应用联合方案化疗，健择1000mg／m^2，静滴半小时，第1、8天；DDP50mg／m^2，静滴，第1、8天。结果：37例中，CR1例，PR15例，CR＋PR16例，总有效率为43．2％。主要不良反应为白细胞及血小板减少，绝大部分病人均能耐受。结论：健择联合顺铂每周用药方案对晚期非小细胞肺癌有较好疗效，不良反应可以耐受。

Clinical Observation of Weekly Chemotherapy of Gemcitabine Combined with cisplatin in the Treatment of Advanced Non- small Cell Lung Cancer

Objective: To evaluate the efficacy and toxicities of weekly chemotherapy of gemcitabine combined with cisplatin for patients with advanced non-small cell Lung cancer. Methods: Thirty-seven patients with advanced non-small cell lung cancer received weekly combined chemotherapy:gemcitabine 1000mg/m~2,infusion during 30 minutes on day1,8, cisplatin 50mg/m~2 introvenous drip on d1,8.Results: One case achieved CR and fifteen cases achieved PR among 37 patients,CR and PR were sixteen, the overall response rate was 43.2%. The main toxicities included leukopenia and thrombocytopenia. Most patients could tolerate them.Conclusion: Weekly Combination chemotherapy of gemcitabine and ciplatin is an effective therapy with acceptable adverse reaction for the treatment of advanced non-small cell lung cancer.[